Vogenx (VOGX)
Develops an oral SGLT1 inhibitor for post-bariatric hypoglycemia.
$32.10
Pre-market−0.34 (−1.05%)
At close$32.44(−2.08%)
Something off on this page? Send us feedback.
Next report
Dec 2, 2026
estimated · in 90 days
EPS estimate
−$0.07
Revenue estimate
—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.07 | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2, 2026 | −$0.07 | — | — | — | — | — | — |